Anivance AI Corporation
Hsinchu
About Anivance AI Corporation
Anivance AI Corporation is a Taiwan-based startup specializing in organ-on-chip platforms integrated with artificial intelligence. Leveraging Taiwan’s strengths in semiconductor and precision manufacturing, we deliver user-friendly, cost-effective organ-on-chip solutions enhanced with Multi-Agent AI, making experimental deployment as simple as plugging in a USB. Our platforms cover lung, liver, heart, kidney, tumor, and rare disease models. With thousands of accumulated datasets from collaborations with seven hospitals and global pharmaceutical companies, we have supported over 20 experimental projects, expanded business across North America, Japan, South Korea, and Europe, and hold 35+ patents protecting our proprietary technologies. We pioneer a “No Animals, No Delays, Just Human Data” vision.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $6.3M
- Funding stage: Seed
- Last round: Seed (Nov 2025)
- Website: anivance.io
- Phone: +886-3-6126258
Industries & Categories
AI Infrastructure, Artificial Intelligence (AI), Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/anivance-ai-corporation-54907 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.